USD 1.33
(-6.34%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 13 Thousand USD | -7.14% |
2022 | 14 Thousand USD | -80.28% |
2021 | 71 Thousand USD | 195.83% |
2020 | 24 Thousand USD | -38.46% |
2019 | 39 Thousand USD | 0.0% |
2018 | - USD | 0.0% |
2017 | - USD | 0.0% |
2016 | - USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 0.0% |
2011 | - USD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | - USD | 0.0% |
2024 Q1 | - USD | 0.0% |
2023 Q4 | 13 Thousand USD | -23.53% |
2023 FY | 13 Thousand USD | -7.14% |
2023 Q1 | 6000.00 USD | -57.14% |
2023 Q2 | 22 Thousand USD | 266.67% |
2023 Q3 | 17 Thousand USD | -22.73% |
2022 Q1 | 54 Thousand USD | -23.94% |
2022 Q4 | 14 Thousand USD | -46.15% |
2022 Q3 | 26 Thousand USD | -35.0% |
2022 FY | 14 Thousand USD | -80.28% |
2022 Q2 | 40 Thousand USD | -25.93% |
2021 Q1 | 14 Thousand USD | -41.67% |
2021 Q4 | 71 Thousand USD | 14.52% |
2021 Q3 | 62 Thousand USD | 148.0% |
2021 Q2 | 25 Thousand USD | 78.57% |
2021 FY | 71 Thousand USD | 195.83% |
2020 Q1 | 29 Thousand USD | -25.64% |
2020 Q2 | 22 Thousand USD | -24.14% |
2020 FY | 24 Thousand USD | -38.46% |
2020 Q3 | 15 Thousand USD | -31.82% |
2020 Q4 | 24 Thousand USD | 60.0% |
2019 Q1 | - USD | 0.0% |
2019 Q4 | 39 Thousand USD | 0.0% |
2019 Q2 | - USD | 0.0% |
2019 Q3 | - USD | 0.0% |
2019 FY | 39 Thousand USD | 0.0% |
2018 FY | - USD | 0.0% |
2018 Q4 | - USD | 0.0% |
2018 Q3 | - USD | 0.0% |
2018 Q2 | - USD | 0.0% |
2018 Q1 | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2017 Q1 | - USD | 0.0% |
2017 FY | - USD | 0.0% |
2017 Q4 | - USD | 0.0% |
2016 FY | - USD | 0.0% |
2016 Q2 | - USD | 0.0% |
2016 Q4 | - USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2015 FY | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2012 Q1 | - USD | 0.0% |
2012 Q3 | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2012 Q2 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
2011 FY | - USD | 0.0% |
2011 Q4 | - USD | 0.0% |
2011 Q3 | - USD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
AIM ImmunoTech Inc. | 495 Thousand USD | 97.374% |
Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
Armata Pharmaceuticals, Inc. | 82.3 Million USD | 99.984% |
Actinium Pharmaceuticals, Inc. | 1.57 Million USD | 99.173% |
Azitra, Inc. | 563.69 Thousand USD | 97.694% |
Chromocell Therapeutics Corporation | - USD | -Infinity% |
Calidi Biotherapeutics, Inc. | 2.06 Million USD | 99.369% |
CEL-SCI Corporation | 11.6 Million USD | 99.888% |
iBio, Inc. | 3.5 Million USD | 99.629% |
Lineage Cell Therapeutics, Inc. | 2.07 Million USD | 99.372% |
MAIA Biotechnology, Inc. | - USD | -Infinity% |
Matinas BioPharma Holdings, Inc. | 2.89 Million USD | 99.551% |
Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | 99.305% |
NovaBay Pharmaceuticals, Inc. | 1.1 Million USD | 98.827% |
NanoViricides, Inc. | - USD | -Infinity% |
Oragenics, Inc. | - USD | -Infinity% |
BiomX Inc. | 5.4 Million USD | 99.759% |
BiomX Inc. | 5.4 Million USD | 99.759% |
Protalix BioTherapeutics, Inc. | 4.62 Million USD | 99.719% |
Palatin Technologies, Inc. | 163.78 Thousand USD | 92.063% |
Scorpius Holdings, Inc. | 12.61 Million USD | 99.897% |